Diacerein Reduces Bone Resorption in Osteoarthritis
Author Information
Author(s): Christelle Boileau, Steeve Kwan, Jean-Pierre Pelletier, Saranette Cheng, Johanne Martel-Pelletier
Primary Institution: Osteoarthritis Research Unit, University of Montreal Hospital Centre
Hypothesis
Diacerein and rhein can inhibit the synthesis of resorptive enzymes and reduce osteoclastic differentiation in osteoarthritis.
Conclusion
Diacerein and rhein may help protect against abnormal subchondral bone remodeling in osteoarthritis by reducing the synthesis of resorptive factors and osteoclast formation.
Supporting Evidence
- Diacerein and rhein reduced MMP-13 production in a dose-dependent manner.
- Both drugs inhibited the IL-1β-induced osteoclast differentiation.
- Statistical significance was reached with the highest tested dose of 20 μg/mL.
Takeaway
This study shows that a medicine called diacerein can help stop bad changes in bones that happen when people have arthritis.
Methodology
The study used enzyme-linked immunosorbent assay and Western blot to evaluate the effects of diacerein and rhein on MMP-13 synthesis and osteoclast differentiation.
Limitations
The study was conducted in vitro, and further in vivo studies are needed to confirm the findings.
Participant Demographics
16 patients with osteoarthritis, average age 72 years, 6 males and 10 females.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website